drugset / Trial / NCT00519701
Hydroxyurea in Young Children With Sickle Cell Anemia
Non-randomizedSingle-groupOpen-labelPrevention
Summary
The purpose of this study is to asses prospectively the safety and efficacy of hydroxyurea therapy in children with Sickle cell Anemia between ages 18 months and 5 years, with special emphasis on the ability of hydroxyurea to prevent or reverse chronic organ damage.
Timeline
- Start
- 2002-04
- Primary completion
- —
- Completion
- 2007-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Hydroxyurea | Other / unclassified | — | — |